LEVODOPA/CARBIDOPA GenPar 250/25 levodopa 250 mg and carbidopa (as monohydrate) 25 mg tablet bottle

Land: Australia

Språk: engelsk

Kilde: Department of Health (Therapeutic Goods Administration)

Aktiv ingrediens:

levodopa, Quantity: 250 mg; carbidopa monohydrate, Quantity: 27 mg (Equivalent: carbidopa, Qty 25 mg)

Tilgjengelig fra:

Arrotex Pharmaceuticals Pty Ltd

Legemiddelform:

Tablet, uncoated

Sammensetning:

Excipient Ingredients: microcrystalline cellulose; pregelatinised maize starch; indigo carmine aluminium lake; crospovidone; magnesium stearate

Administreringsrute:

Oral

Enheter i pakken:

100 tablets

Resept typen:

(S4) Prescription Only Medicine

Indikasjoner:

LEVODOPA/CARBIDOPA GenPar is indicated for the treatment of Parkinson's disease and syndrome. It is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. LEVODOPA/CARBIDOPA GenPar frequently is helpful in the management of tremor, dysphagia, sialorrhoea and postural instability associated with Parkinson's disease and syndrome.

Produkt oppsummering:

Visual Identification: Round, light blue uncoated tablets with 'C' on one side and '20' on the other side.; Container Type: Bottle; Container Material: HDPE; Container Life Time: 12 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Autorisasjon status:

Registered

Autorisasjon dato:

2018-01-11